NEW YORK (GenomeWeb) – WaveSense, a company developing a platform for rare cell isolation and enrichment, said today that it has received CE-IVD marking for its technologies.

The approval includes the company's EpiSep direct-to-slide cell enrichment technology, as well as its proprietary paramagnetic bead technology, which allows for selective isolation of cells that express CD138.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.